Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept.

Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept.
Z Rheumatol. 2017 Jan 26;:
Authors: Jung JH, Kim JH, Song GG
Abstract
Tumor necrosis factor alpha (TNF-α) inhibitors effectively treat sarcoidosis, but can, paradoxically, induce sarcoidosis. The TNF-α inhibitor etanercept is most commonly associated with paradoxical sarcoidosis, which has previously been reported to be resolved by adalimumab. However, we describe the case of a patient with ankylosing spondylitis and adalimumab-induced sarcoidosis not aggravated by switching to etanercept, thus indicating that etanercept could be a treatment option for patients who develop paradoxical sarcoid-like reactions after treatment with other TNF-α inhibitors.
PMID: 28124746 [PubMed - as supplied by publisher]

Source: Zeitschrift fur Rheumatologie - January 25, 2017 Category: Rheumatology Authors: Jung JH, Kim JH, Song GG Tags: Z Rheumatol Source Type: research